Tango Therapeutics (TNGX) Expected to Announce Earnings on Thursday

Tango Therapeutics (NASDAQ:TNGX) is expected to be issuing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.31) per share and revenue of $0.5560 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 5, 2026 at 9:00 AM ET.

Tango Therapeutics Stock Up 4.3%

Shares of NASDAQ TNGX opened at $12.73 on Tuesday. The stock’s fifty day simple moving average is $11.08 and its 200 day simple moving average is $9.08. The stock has a market capitalization of $1.71 billion, a price-to-earnings ratio of -13.69 and a beta of 1.75. Tango Therapeutics has a 52-week low of $1.03 and a 52-week high of $13.60.

Insider Activity at Tango Therapeutics

In related news, CFO Daniella Beckman sold 10,317 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $12.26, for a total transaction of $126,486.42. Following the transaction, the chief financial officer directly owned 184,297 shares of the company’s stock, valued at approximately $2,259,481.22. The trade was a 5.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Barbara Weber sold 30,519 shares of Tango Therapeutics stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $12.26, for a total transaction of $374,162.94. Following the sale, the director directly owned 1,629,254 shares of the company’s stock, valued at $19,974,654.04. This trade represents a 1.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 59,288 shares of company stock valued at $726,871. Corporate insiders own 7.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd raised its stake in shares of Tango Therapeutics by 139.7% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock worth $35,000 after purchasing an additional 15,037 shares in the last quarter. Global Retirement Partners LLC bought a new position in shares of Tango Therapeutics during the 4th quarter valued at $35,000. Legal & General Group Plc lifted its stake in shares of Tango Therapeutics by 30.7% in the 2nd quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock valued at $36,000 after purchasing an additional 1,640 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in Tango Therapeutics by 44.3% in the second quarter. Tower Research Capital LLC TRC now owns 9,473 shares of the company’s stock worth $49,000 after purchasing an additional 2,907 shares in the last quarter. Finally, Northeast Financial Consultants Inc acquired a new position in Tango Therapeutics during the second quarter worth $51,000. Hedge funds and other institutional investors own 78.99% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on TNGX. Weiss Ratings restated a “sell (e+)” rating on shares of Tango Therapeutics in a report on Wednesday, January 21st. Stifel Nicolaus assumed coverage on shares of Tango Therapeutics in a report on Wednesday, December 3rd. They set a “buy” rating and a $15.00 price target on the stock. Wall Street Zen upgraded shares of Tango Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, December 13th. Wolfe Research began coverage on shares of Tango Therapeutics in a research report on Tuesday, November 18th. They set a “peer perform” rating on the stock. Finally, Piper Sandler boosted their target price on shares of Tango Therapeutics from $11.00 to $14.00 and gave the company an “overweight” rating in a research note on Friday, January 16th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Tango Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $15.50.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.